Janus Henderson Group PLC Decreases Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Janus Henderson Group PLC decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,280,866 shares of the medical research company’s stock after selling 67,747 shares during the period. Janus Henderson Group PLC owned about 4.92% of NeoGenomics worth $98,735,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System bought a new stake in shares of NeoGenomics during the 4th quarter valued at about $1,032,000. Oak Family Advisors LLC grew its position in NeoGenomics by 3.4% during the fourth quarter. Oak Family Advisors LLC now owns 99,978 shares of the medical research company’s stock valued at $1,618,000 after buying an additional 3,241 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in NeoGenomics by 19.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,707 shares of the medical research company’s stock valued at $497,000 after buying an additional 5,064 shares during the last quarter. Handelsbanken Fonder AB raised its position in NeoGenomics by 7.0% in the fourth quarter. Handelsbanken Fonder AB now owns 19,900 shares of the medical research company’s stock worth $322,000 after acquiring an additional 1,300 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of NeoGenomics by 17.8% during the 4th quarter. Jennison Associates LLC now owns 591,556 shares of the medical research company’s stock worth $9,571,000 after acquiring an additional 89,473 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Trading Up 4.6 %

Shares of NASDAQ:NEO traded up $0.79 during trading on Wednesday, hitting $18.06. The company had a trading volume of 348,415 shares, compared to its average volume of 853,988. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 7.22. The company has a fifty day simple moving average of $13.97 and a two-hundred day simple moving average of $14.69. NeoGenomics, Inc. has a one year low of $11.03 and a one year high of $21.22.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.71%. The company had revenue of $164.50 million during the quarter, compared to analyst estimates of $161.82 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. NeoGenomics’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities research analysts anticipate that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Benchmark restated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday. Stephens reaffirmed an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Tuesday. TD Cowen cut their price objective on NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Craig Hallum assumed coverage on shares of NeoGenomics in a research note on Wednesday, May 1st. They set a “buy” rating and a $26.00 target price on the stock. Finally, BTIG Research dropped their price target on shares of NeoGenomics from $23.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.